Table 2.
CU201 growth inhibition of cell lines of different histology
| Cell type | n | Average IC50, μM | Range, μM |
|---|---|---|---|
| Normal lung cell lines* | 2 | 6.2 | 5.3–7.0 |
| SCLC† | 9 | 2.1 | 1.0–3.5 |
| SHP-77‡ | 1.0 | ||
| H69‡ | 1.0 | ||
| H69VPR2‡ | 1.5 | ||
| NSCLC§ | 5 | 4.1 | 1.0–5.0 |
| SW1573 | 5.0 | ||
| SW2R120¶ | 4.5 | ||
| SW2R160¶ | 5.0 | ||
| Prostate‖ carcinomas | 5 | 3.0 | 3.3–5.3 |
| Breast** carcinomas | 5 | 2.6 | 1.3–3.9 |
*
Normal lung fibroblast cell lines: IMR90 and CCD-16Lu.
†
SCLC: H69, H69VPR2, H209, H345, H740, H82, SHP-77, DMS114, and H1048.
‡
SCLC: SHP-77 overexpresses multidrug-resistant protein (not drug selected in vitro; ref. 29); H69-parental, H69VPR2 overexpresses multidrug-resistant protein (drug selected in vitro; ref. 30).
§
NSCLC: A549, H157, SW1573, SW2R120, and SW2R160.
¶
NSCLC: SW1573-parental, SW2R120, and SW2R160 overexpress lung-resistant protein (drug selected in vitro; ref. 31).
‖
Prostate carcinomas: LNCaP, DU145, TSU, PC3, and PPC1.
**
Breast carcinomas: ZR75, T47DV, MDAMB231, MCF7, and SKBR3.